Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 359

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 359
---
15,500,000 units (“Units”) (with respect to the Class A common stock included in the Units being offered
(the “Public Shares”)) at $10.00 per Unit generating gross proceeds of $155,000,000, which is discussed in Note 3. The Company
has selected December 31 as its fiscal year end.

Simultaneously with the closing of the IPO, the
Company consummated the sale of 845,000 units (“Private Placement Units”) (with respect to the Class A common stock included
in the Private Placement Units offered, the “Private Placement Shares”) at a price of $10.00 per Private Placement Unit in
a private placement to the Company’s sponsor, Phoenix Biotech Sponsor, LLC (the “Sponsor”), Cantor Fitzgerald &
Co. (“Cantor”) and Cohen & Company Capital Markets, a division of J.V.B. Financial Group, LLC (“CCM”), generating
gross proceeds of $8,450,000, which is described in Note 4.

Simultaneously with the closing of the IPO, the
Company consummated the sale of 2,000,000 additional Units upon receiving notice of the underwriter’s election to partially exercise
its overallotment option (“Overallotment Units”), generating additional gross proceeds of $20,000,000 and incurring additional
offering costs of $1,400,000 in underwriting fees, all of which are deferred until the completion of the Company’s initial business
combination. Simultaneously with the exercise of the overallotment, the Company consummated the Private Placement of an additional 40,000
Private Placement Units to the Sponsor and CCM, generating gross proceeds of $400,000.

Offering costs for the IPO and exercise of the
overallotment option amounted to $12,729,318, consisting of $2,635,000 of underwriting fees, $9,150,000 of deferred underwriting fees
payable (which are held in the Trust Account (defined below)) and $944,318 of other costs. As described in Note 6, the $9,150,000 of
deferred underwriting fees payable is contingent upon the consummation of a business combination by January 8, 2024, subject to the terms
of the underwriting agreement.

Following the closing of the IPO, $178,500,000
($10.20 per Unit) from the net proceeds of the sale of the